Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory properties of topical CRx-197 in mild to moderate atopic dermatitis
2008-002284-13Phase 2Active
- Sponsor
- CombinatoRx
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CRx-197 in atopic dermatitis (AD) (2 arms), sponsored by CombinatoRx. Primary endpoints: Primary effectiveness endpoint and Tolerability and safety. Started Oct 2008; status: active.
02
Drugs
CRx-197
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2008-002284-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002284-13.